Press Release: Penn team identifies promising new target for gum disease treatment

University of Pennsylvania researchers have been searching for ways to prevent, halt and reverse periodontitis. In a report published in the Journal of Immunology, they describe a promising new target: a component of the immune system called complement. Treating monkeys with a complement inhibitor successfully prevented the inflammation and bone loss that is associated with periodontitis, making this a promising drug for treating humans with the disease.

Press Release: Penn immunologist to develop drugs for renal disease

John Lambris, the Dr. Ralph and Sallie Weaver Professor of Research Medicine in the department of pathology and laboratory medicine at Penn’s Perelman School of Medicine, is part of an $8 million European Union FP7 grant, which has been awarded to a consortium of academic institutions and the biotech company called Amyndas Pharmaceuticals (based on Penn technology developed in the Lambris lab).

Almanac, Vol. 60, No. 19